Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27619373 | 0.80 | CA2 (0.45) | CA2CA1CA9 | |
| SCHEMBL27619297 | 0.80 | CA2 (0.45) | CA2CA1CA9 | |
| SCHEMBL15389821 | 0.80 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL27619260 | 0.80 | CA2 (0.45) | CA2CA1CA9 | |
| SCHEMBL28022250 | 0.77 | CA2 (0.42) | CA2CA1CA9 | |
| SCHEMBL15389822 | 0.77 | CA2 (0.42) | CA2CA1CA9 | |
| SCHEMBL5144300 | 0.77 | CA2 (0.37) | CA2CA1CA9CA12CA4 | |
| SCHEMBL25509882 | 0.73 | CA2 (0.44) | CA2CA1CA9CA12CA4 | |
| SCHEMBL25510344 | 0.73 | CA2 (0.44) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1063303 | 0.72 | CYP2D6 (0.43) | CA2CA1CA9CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914232-B1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1914232-A1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | CA2 1483/4885CA1 1223/4885CA9 3020/4885 |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | CA2 1483/4885CA1 1223/4885CA9 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.